Revolution Medicines, Inc.

For the period ended Dec 31, 2025. Filed Feb 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 25, 2026

RVMD$193.06-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

	Year Ended December 31,
	2025	2024	2023
Revenue:
Collaboration revenue	$—	$—	$11,580
Total revenue	—	—	11,580
Operating expenses:
Research and development	987,332	592,225	423,144
General and administrative	195,037	97,299	75,621
Total operating expenses	1,182,369	689,524	498,765
Loss from operations	(1,182,369)	(689,524)	(487,185)
Non-operating income (expense), net:
Interest income	90,694	86,883	47,482
Interest expense	(24,231)	—	—
Change in fair value of warrant liability and contingent earn-out shares	(15,358)	4,323	115
Other expense, net	(37)	(2,528)	(303)
Total non-operating income, net	51,068	88,678	47,294
Loss before income taxes	(1,131,301)	(600,846)	(439,891)
Benefit from income taxes	—	753	3,524
Net loss	$(1,131,301)	$(600,093)	$(436,367)
Net loss per share attributable to common stockholders, basic and diluted	$(5.95)	$(3.58)	$(3.86)
Weighted-average common shares used to compute net loss per share, basic and diluted	190,129,154	167,737,672	113,149,869
Comprehensive loss:
Net loss	$(1,131,301)	$(600,093)	$(436,367)
Other comprehensive gain:
Unrealized gain on investments, net	1,916	777	2,324
Comprehensive loss	$(1,129,385)	$(599,316)	$(434,043)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.